Literature DB >> 7267475

The effect of prenylamine on the QT interval of the resting electrocardiogram in patients with angina pectoris.

D Oakley, K Jennings, R Puritz, D Krikler, D Chamberlain.   

Abstract

Resting ECGs were recorded in 29 patients with angina pectoris before, during and after treatment with prenylamine 180 mg daily. The QT interval became significantly prolonged after one week of treatment. The prolongation persisted as long as therapy was continued, which was up to 6 months. After withdrawal of treatment the QT interval returned to normal within 2 weeks. In this study no serious problems were encountered by those patients in whom the QT interval was prolonged.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7267475      PMCID： PMC2426055          DOI： 10.1136/pgmj.56.661.753

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  6 in total

1.  Utility and limitations of intravenous quinidine in arrhythmias.

Authors:  L J ACIERNO; R GUBNER
Journal:  Am Heart J       Date:  1951-05       Impact factor: 4.749

2.  Ventricular arrhythmias caused by prenylamine.

Authors:  R Puritz; M A Henderson; S N Baker; D A Chamberlain
Journal:  Br Med J       Date:  1977-09-03

3.  Prenylamine in treatment of angina.

Authors:  H Tucker; P Carson; N Bass; J Massey
Journal:  Br Heart J       Date:  1974-10

4.  [Syncope by volley of ventricular spikes induced or encouraged by prenylamine].

Authors:  J L Bens; M Duboisset; J C Quiret; J P Lesbre; P Bernasconi
Journal:  Arch Mal Coeur Vaiss       Date:  1973-11

5.  Atypical ventricular tachycardia as a manifestation of disopyramide toxicity.

Authors:  R S Meltzer; E W Robert; M McMorrow; R P Martin
Journal:  Am J Cardiol       Date:  1978-12       Impact factor: 2.778

6.  [Adverse effects of drugs: syncope due to prenylamine (author's transl)].

Authors:  G Jacovella; F S Vajola
Journal:  G Ital Cardiol       Date:  1976
  6 in total
  3 in total

Review 1.  QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.

Authors:  M Zehender; S Hohnloser; H Just
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

2.  Ventricular tachycardia precipitated by sodium iothalamate (Conray 420) injection during prenylamine treatment: a predictable adverse drug interaction.

Authors:  J S Duncan; L E Ramsay
Journal:  Postgrad Med J       Date:  1985-05       Impact factor: 2.401

Review 3.  Withdrawal of prenylamine: perspectives on pharmacological, clinical and regulatory outcomes following the first QT-related casualty.

Authors:  Rashmi R Shah; Peter D Stonier
Journal:  Ther Adv Drug Saf       Date:  2018-06-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.